insurance companies that cover glp-1 drugs Costly are Rarely Covered for Weight Loss by Marketplace Plans Weight loss drugs can help

The study highlights that after stopping GLP-1 medications, many patients resume treatment or try alternatives, influencing weight management strategies.

The airball comes as Novo scrambles to regain a majority share of the GLP-1 market.

Summary Obesity is a chronic progressive disease with increasing prevalence in the United States and around the world

It results from the metabolic consequences due to a lack of insulin secretion or impaired insulin activity in diabetes leading to dysregulated pathophysiologic pathways resulting in excessive ketone body formation

22, 2025, when the U.S Food and Drug Administration (FDA) approved oral Wegovy by Novo Nordisk as the first daily, oral GLP-1 pill for weight management.

It details preclinical and clinical evidence linking GLP-1 receptor activation to cardiovascular, renal, hepatic, neural, and joint anti-inflammatory effects while outlining uncertainties and future research needs.